AAPL349.73+1.51 (+0.43%) ▲|ABBV283.49-1.45 (-0.51%) ▼|ABT102.40-0.12 (-0.11%) ▼|ACN245.90-12.84 (-4.96%) ▼|ADBE266.96-3.59 (-1.33%) ▼|AMAT376.93+1.35 (+0.36%) ▲|AMD516.69+8.76 (+1.72%) ▲|AMGN440.77-6.51 (-1.46%) ▼|AMT192.35+10.78 (+5.94%) ▲|AMZN248.56-1.82 (-0.73%) ▼|AVGO324.87+1.63 (+0.50%) ▲|AXP315.83-9.34 (-2.87%) ▼|BA185.04-2.51 (-1.34%) ▼|BAC50.68-0.40 (-0.78%) ▼|BKNG157.29-3.81 (-2.37%) ▼|BLK1,121.22-16.08 (-1.41%) ▼|BMY61.77-1.23 (-1.95%) ▼|BNY144.11-1.21 (-0.83%) ▼|BRK-B545.91-1.07 (-0.19%) ▼|C120.89-1.62 (-1.32%) ▼|CAT683.80-20.26 (-2.88%) ▼|CL94.85-2.55 (-2.61%) ▼|CMCSA22.81-0.03 (-0.13%) ▼|COF200.80-2.64 (-1.30%) ▼|COP150.53+4.90 (+3.36%) ▲|COST1,010.61-7.60 (-0.75%) ▼|CRM245.87-4.43 (-1.77%) ▼|CSCO105.68+0.79 (+0.75%) ▲|CVS93.66-0.82 (-0.87%) ▼|CVX230.56+3.88 (+1.71%) ▲|DE635.53-8.10 (-1.26%) ▼|DHR226.74-3.01 (-1.31%) ▼|DIS112.11-1.02 (-0.90%) ▼|DUK124.40-1.01 (-0.80%) ▼|EMR158.70-1.59 (-0.99%) ▼|FDX296.83-7.10 (-2.33%) ▼|GD346.85-3.95 (-1.12%) ▼|GE284.21-9.33 (-3.18%) ▼|GEV807.01-20.41 (-2.47%) ▼|GILD156.36-0.84 (-0.53%) ▼|GM75.19-2.02 (-2.62%) ▼|GOOG320.81+0.05 (+0.01%) ▲|GOOGL323.99-0.23 (-0.07%) ▼|GS882.41-8.89 (-1.00%) ▼|HD319.03-8.70 (-2.65%) ▼|HON212.59-5.72 (-2.62%) ▼|IBM252.08-0.03 (-0.01%) ▼|INTC86.50+1.01 (+1.18%) ▲|INTU349.29-5.62 (-1.58%) ▼|ISRG452.05+8.20 (+1.85%) ▲|JNJ263.59-4.03 (-1.50%) ▼|JPM331.33-5.21 (-1.55%) ▼|KO93.27-2.08 (-2.18%) ▼|LIN505.84-4.52 (-0.89%) ▼|LLY1,277.92-28.77 (-2.20%) ▼|LMT593.98+4.07 (+0.69%) ▲|LOW198.83-5.55 (-2.71%) ▼|LRCX227.65-2.51 (-1.09%) ▼|MA623.08-10.14 (-1.60%) ▼|MCD248.54-4.09 (-1.62%) ▼|MDLZ63.93-1.26 (-1.93%) ▼|MDT95.79-0.80 (-0.83%) ▼|META644.37-4.48 (-0.69%) ▼|MMM170.98-4.58 (-2.61%) ▼|MO75.18-0.89 (-1.17%) ▼|MRK144.14-3.10 (-2.10%) ▼|MS181.46-2.52 (-1.37%) ▼|MSFT523.07+1.99 (+0.38%) ▲|MU881.87+25.38 (+2.96%) ▲|NEE81.43-0.48 (-0.58%) ▼|NFLX67.03-0.02 (-0.03%) ▼|NKE37.49-0.83 (-2.17%) ▼|NOW155.52-1.48 (-0.94%) ▼|NVDA212.66+0.45 (+0.21%) ▲|ORCL126.20+0.66 (+0.52%) ▲|PEP135.89-2.94 (-2.12%) ▼|PFE29.90-0.52 (-1.71%) ▼|PG162.04-2.46 (-1.50%) ▼|PLTR194.70-1.50 (-0.76%) ▼|PM201.34-0.40 (-0.20%) ▼|QCOM173.80+0.97 (+0.56%) ▲|RTX190.57-4.14 (-2.13%) ▼|SBUX101.23-0.68 (-0.67%) ▼|SCHW90.31-1.13 (-1.24%) ▼|SO93.14-0.69 (-0.73%) ▼|SPG211.43-0.61 (-0.29%) ▼|T21.53-1.22 (-5.34%) ▼|TMO667.70-8.84 (-1.31%) ▼|TMUS152.48-6.32 (-3.98%) ▼|TSLA372.08-2.51 (-0.67%) ▼|TXN281.50+2.00 (+0.72%) ▲|UBER67.71-1.36 (-1.97%) ▼|UNH421.78-3.21 (-0.75%) ▼|UNP289.88-8.22 (-2.76%) ▼|UPS99.36-2.16 (-2.13%) ▼|USB59.13-0.89 (-1.48%) ▼|V407.29-7.05 (-1.70%) ▼|VZ43.92-1.28 (-2.83%) ▼|WFC82.00-1.01 (-1.22%) ▼|WMT120.23-0.89 (-0.73%) ▼|XOM181.49+3.26 (+1.83%) ▲|AAPL349.73+1.51 (+0.43%) ▲|ABBV283.49-1.45 (-0.51%) ▼|ABT102.40-0.12 (-0.11%) ▼|ACN245.90-12.84 (-4.96%) ▼|ADBE266.96-3.59 (-1.33%) ▼|AMAT376.93+1.35 (+0.36%) ▲|AMD516.69+8.76 (+1.72%) ▲|AMGN440.77-6.51 (-1.46%) ▼|AMT192.35+10.78 (+5.94%) ▲|AMZN248.56-1.82 (-0.73%) ▼|AVGO324.87+1.63 (+0.50%) ▲|AXP315.83-9.34 (-2.87%) ▼|BA185.04-2.51 (-1.34%) ▼|BAC50.68-0.40 (-0.78%) ▼|BKNG157.29-3.81 (-2.37%) ▼|BLK1,121.22-16.08 (-1.41%) ▼|BMY61.77-1.23 (-1.95%) ▼|BNY144.11-1.21 (-0.83%) ▼|BRK-B545.91-1.07 (-0.19%) ▼|C120.89-1.62 (-1.32%) ▼|CAT683.80-20.26 (-2.88%) ▼|CL94.85-2.55 (-2.61%) ▼|CMCSA22.81-0.03 (-0.13%) ▼|COF200.80-2.64 (-1.30%) ▼|COP150.53+4.90 (+3.36%) ▲|COST1,010.61-7.60 (-0.75%) ▼|CRM245.87-4.43 (-1.77%) ▼|CSCO105.68+0.79 (+0.75%) ▲|CVS93.66-0.82 (-0.87%) ▼|CVX230.56+3.88 (+1.71%) ▲|DE635.53-8.10 (-1.26%) ▼|DHR226.74-3.01 (-1.31%) ▼|DIS112.11-1.02 (-0.90%) ▼|DUK124.40-1.01 (-0.80%) ▼|EMR158.70-1.59 (-0.99%) ▼|FDX296.83-7.10 (-2.33%) ▼|GD346.85-3.95 (-1.12%) ▼|GE284.21-9.33 (-3.18%) ▼|GEV807.01-20.41 (-2.47%) ▼|GILD156.36-0.84 (-0.53%) ▼|GM75.19-2.02 (-2.62%) ▼|GOOG320.81+0.05 (+0.01%) ▲|GOOGL323.99-0.23 (-0.07%) ▼|GS882.41-8.89 (-1.00%) ▼|HD319.03-8.70 (-2.65%) ▼|HON212.59-5.72 (-2.62%) ▼|IBM252.08-0.03 (-0.01%) ▼|INTC86.50+1.01 (+1.18%) ▲|INTU349.29-5.62 (-1.58%) ▼|ISRG452.05+8.20 (+1.85%) ▲|JNJ263.59-4.03 (-1.50%) ▼|JPM331.33-5.21 (-1.55%) ▼|KO93.27-2.08 (-2.18%) ▼|LIN505.84-4.52 (-0.89%) ▼|LLY1,277.92-28.77 (-2.20%) ▼|LMT593.98+4.07 (+0.69%) ▲|LOW198.83-5.55 (-2.71%) ▼|LRCX227.65-2.51 (-1.09%) ▼|MA623.08-10.14 (-1.60%) ▼|MCD248.54-4.09 (-1.62%) ▼|MDLZ63.93-1.26 (-1.93%) ▼|MDT95.79-0.80 (-0.83%) ▼|META644.37-4.48 (-0.69%) ▼|MMM170.98-4.58 (-2.61%) ▼|MO75.18-0.89 (-1.17%) ▼|MRK144.14-3.10 (-2.10%) ▼|MS181.46-2.52 (-1.37%) ▼|MSFT523.07+1.99 (+0.38%) ▲|MU881.87+25.38 (+2.96%) ▲|NEE81.43-0.48 (-0.58%) ▼|NFLX67.03-0.02 (-0.03%) ▼|NKE37.49-0.83 (-2.17%) ▼|NOW155.52-1.48 (-0.94%) ▼|NVDA212.66+0.45 (+0.21%) ▲|ORCL126.20+0.66 (+0.52%) ▲|PEP135.89-2.94 (-2.12%) ▼|PFE29.90-0.52 (-1.71%) ▼|PG162.04-2.46 (-1.50%) ▼|PLTR194.70-1.50 (-0.76%) ▼|PM201.34-0.40 (-0.20%) ▼|QCOM173.80+0.97 (+0.56%) ▲|RTX190.57-4.14 (-2.13%) ▼|SBUX101.23-0.68 (-0.67%) ▼|SCHW90.31-1.13 (-1.24%) ▼|SO93.14-0.69 (-0.73%) ▼|SPG211.43-0.61 (-0.29%) ▼|T21.53-1.22 (-5.34%) ▼|TMO667.70-8.84 (-1.31%) ▼|TMUS152.48-6.32 (-3.98%) ▼|TSLA372.08-2.51 (-0.67%) ▼|TXN281.50+2.00 (+0.72%) ▲|UBER67.71-1.36 (-1.97%) ▼|UNH421.78-3.21 (-0.75%) ▼|UNP289.88-8.22 (-2.76%) ▼|UPS99.36-2.16 (-2.13%) ▼|USB59.13-0.89 (-1.48%) ▼|V407.29-7.05 (-1.70%) ▼|VZ43.92-1.28 (-2.83%) ▼|WFC82.00-1.01 (-1.22%) ▼|WMT120.23-0.89 (-0.73%) ▼|XOM181.49+3.26 (+1.83%) ▲|
10.7 C
New York
Friday, October 23, 2026

Tag: treatment

Strobilurin Market worth $6.88 billion by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 2, 2025 /PRNewswire/ -- The strobilurin market is projected to expand from USD 5.53 billion in 2025 to USD 6.88...

Arbele Wins Top Prize at BCIC’s 4th Annual Biomedical Pitch Competition

BOSTON, July 2, 2025 /PRNewswire/ -- Arbele Limited, a Hong Kong-based biotech company, was awarded first place at the 4th Biomedical Pitch Competition, hosted...

Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of...

As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52...

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

-  500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

FSI ANNOUNCES RECEIPT OF A $2.5 MILLION PAYMENT FOR ASSISTING IN THE DEVELOPMENT A NEW FOOD GRADE PRODUCT

TABER, ALBERTA, July 01, 2025 (GLOBE NEWSWIRE) -- FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE Amex: FSI), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. FSI is also increasing its presense in the food and nutrition supplement manufacturing markets. Today the Company announces it has received payment of US$2.5million for assisting in developing a new food grade product.

EZGO ANNOUNCES FINANCIAL RESULTS FOR THE SIX MONTHS ENDED MARCH 31, 2025

CHANGZHOU, China, July 1, 2025 /PRNewswire/ -- EZGO Technologies Ltd. (Nasdaq: EZGO) ("EZGO" or "we", "our", or the "Company"), a leading short-distance transportation solutions...

GlucoTru Pro Releases 2025 Health Integrity Update on Blood Pressure & Blood Sugar Balance Innovation

In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.
In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.

Florida Cancer Specialists & Research Institute Announces Addition Of Specialized Gynecologic Oncology Services in Tampa Bay Communities

Heather Miller, MD Joins Statewide Practice FORT MYERS, Fla., July 1, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) ) is pleased...

Novo Holdings portfolio company Kate Farms acquired by Danone

Novo Holdings led Kate Farms' Series C financing in 2022 and supported its continued growth as the company's largest institutional investor Transaction highlights the Planetary...

ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware

WINSTON-SALEM, N.C., July 01, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the completion of the domestication process to change the jurisdiction of incorporation of the Company from the Cayman Islands to Delaware. The domestication was approved by shareholders of the Company at its Annual General Meeting held on May 29, 2025. Effective as of July 1, 2025, each (i) Class A ordinary share automatically converted into one share of Class A common stock of ProKidney Corp., a Delaware corporation and (ii) each Class B ordinary share automatically converted into one share of Class B common stock of ProKidney. ProKidney common stock will begin trading on July 2, 2025, and the Company's trading symbol on the Nasdaq Stock Market will remain unchanged as "PROK." The Company’s CUSIP number relating to its Class A common stock changed to 74291D 104. The Company does not anticipate any impact to day-to-day business operations as a result of the domestication.

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatment